(HealthDay): Use of certain classes of diabetes medications before severe COVID-19 infection is associated with lower mortality in patients with diabetes, according to a study published online June 16 in Diabetes care.
Anna R. Kahkoska, Ph.D., of the University of North Carolina at Chapel Hill, and colleagues compared the use of the glucagon-like peptide 1 receptor agonist (GLP1-RA). GLP1-RA) and the inhibitor of sodium-glucose cotransporter 2 (SGLT2i) against premorbid. use of dipeptidyl peptidase 4 (DPP4i) inhibitor in terms of severity of outcomes with severe infection of acute respiratory syndrome by coronavirus 2 (SARS-CoV-2). The analysis included 12,446 individuals identified through the collaborative data set of national COVID cohorts (January 2018 to February 2021) with a prescription for GLP1-RA, SGLT2i or DPP4i within 24 months of the trial positive SARS-CoV-2 polymerase chain reaction.
The researchers found that 60 days mortality was 3.11% overall, but varied according to the use of premorbid drugs (2.06% with the use of GLP1-RA, 2.32% with the use of SGLT2i and 5.67 % with the use of DPP4i). There was a 60-day lower mortality with the use of GLP1-RA and SGLT2i versus the use of DPP4i (probability ratios, 0.54 and 0.66, respectively). Similar associations were observed between the use of both drugs and total mortality, emergency room visits, and hospitalizations.
“Among SARS-CoV-2-positive adults, premorbid use of GLP1-RA and SGLT2i, compared with DPP4i use, was associated with lower probabilities of mortality and other adverse outcomes, although users of DPP4i were larger and generally sicker, ”the authors write.
Several authors revealed financial links with the pharmaceutical industry.
Summary / Full text (subscription or payment may be required)
Copyright © 2021 HealthDay. All rights reserved.
Citation: The type of medication for diabetes can affect the severe outcomes of COVID-19 (2021, June 30) recovered on June 30, 2021 at https://medicalxpress.com/news/2021-06-medication-diabetes -affect-severe-covid-.html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.